TEVA PHARMACEUTICAL INDUSTRIES LTD(TEVA)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TEVA at 56.7/100 on a 32-signal composite quality model, placing it at rank #1,138 of 2,962 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), TEVA PHARMACEUTICAL INDUSTRIES LTD reports quarterly revenue of $4.1B, net income of $-576.0M, free cash flow of $307.0M. Top institutional holders of TEVA by reported 13-F value include BlackRock, Harel Insurance Investments & Financial Services Ltd., Phoenix Financial Ltd., based on the most recent SEC filings. TEVA trades on the NYSE exchange and files with the SEC under CIK 818686. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TEVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TEVA PHARMACEUTICAL INDUSTRIES LTD directly from SEC EDGAR.
AI Quality Score
56.7/100
AI Rank
#1,138
Revenue
$4.1B
Net Income
$-576.0M
Free Cash Flow
$307.0M
TEVA key financials by period
TEVA PHARMACEUTICAL INDUSTRIES LTD reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$17.3B
$1.4B
12.5%
FY 2024
10-K
$16.5B
$-1.6B
-1.8%
FY 2023
10-K
$15.8B
$-559.0M
2.7%
FY 2022
10-K
$14.9B
$-2.4B
-14.7%
FY 2021
10-K
$15.9B
$417.0M
10.8%
FY 2020
10-K
$16.7B
$-4.0B
-21.4%
Institutions holding TEVA
Institutional investors reporting a position in TEVA PHARMACEUTICAL INDUSTRIES LTD on SEC Form 13F.
